Home >
Medicine Info >
Path 30 MG Tablet
Loading interface...

Path 30 MG Tablet

Manufactured byLupin Ltd.
ContainsPioglitazone
Description
Path 30 MG Tablet is an anti-diabetic medicine used to control high blood sugar levels in type II Diabetes Mellitus (when your body cannot use the insulin it makes effectively to move sugar from the blood into the cells). This medicine works by improving your body's response to insulin (a chemical substance that helps control blood sugar levels) and lowering the production of sugar in the liver. Path 30 MG Tablet has some side effects like headache, muscle pain, stuffy nose, sore throat, low blood sugar levels, weight gain, etc. Consult your doctor if they bother you for a longer time or worsen. Path 30 MG Tablet is to be taken once daily with or without food. Your doctor will determine the dose based on your clinical condition and therapeutic response, alone or in combination with other medications. Do not take more than the recommended dose as it may lead to side effects. Take it every day at the same time for ease of remembering and to maintain a constant level of this medicine in the blood. Do not discontinue this medication without consulting your doctor as it may worsen your condition. Path 30 MG Tablet is not recommended if you are allergic to it or have heart failure (the heart is unable to pump enough blood throughout the body), type 1 diabetes mellitus (when your body does not produce insulin or makes very little insulin), diabetic ketoacidosis (increase in the levels of blood acids called ketones), liver problems, or bladder cancer. Inform your doctor if you have kidney or eye conditions along with any other health issues you have and the medicines you use. Path 30 MG Tablet is not recommended for use in children below 18 years of age as the safety and efficacy data are not available. Consult your doctor if you are pregnant or breastfeeding before taking this medicine.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Substitutes

List of substitutes for Path 30 MG Tablet

Diavista 30 MG Tablet
Dr. Reddys Laboratories Ltd.
Piodart 30 MG Tablet
Biocon Ltd.
Pioglit 30 MG Tablet
Sun Pharma Laboratories Ltd.
Piozulin 30 MG Tablet
Cadila Pharmaceuticals Ltd.
Precitrol 30 MG Tablet
Merck Consumer Healthcare Ltd.

Side effects

Major & minor side effects for Path 30 MG Tablet

  • Low blood sugar levels (hypoglycaemia)
  • Bloody and Cloudy urine
  • Painful urination
  • Swelling of face, lips, eyelids, tongue, hands and feet
  • Irregular heartbeat
  • Weight gain
  • Upper respiratory tract infection
  • Headache
  • Fracture of bones
  • Muscle pain
  • Stuffy nose
  • Sore throat

Uses of Path 30 MG Tablet

What is it prescribed for?

  • Type II Diabetes Mellitus
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The time taken for Path 30 MG Tablet to show its effect is not clinically known.
  • How long do the effects of this medicine last?
    The effect of Path 30 MG Tablet lasts for approximately 24 hours.
  • Is it safe to consume alcohol while taking this medicine?
    Avoid consumption of alcohol during treatment with Path 30 MG Tablet due to the increased risk of side effects.
  • Is this a habit forming medicine?
    No habit-forming tendency has been reported for Path 30 MG Tablet.
  • Can this medicine be taken during pregnancy?
    Path 30 MG Tablet is not recommended for use during pregnancy unless absolutely necessary. Consult your doctor before taking this medicine if you are pregnant.
  • Can this medicine be taken while breast-feeding?
    Path 30 MG Tablet is not recommended for use if you are breastfeeding as it may cause undesired effects in your infant. Consult your doctor to understand the risks and benefits before taking this medicine.

Allergy

Avoid taking Path 30 MG Tablet if you are allergic to it. Seek immediate medical attention if you notice any symptoms such as skin rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, breathing difficulty, etc.

Heart Failure

Heart failure is when your heart is unable to pump enough blood throughout the body. Path 30 MG Tablet is not recommended for use if you had moderate-to-severe heart failure due to the increased risk of worsening your health condition.

Diabetic ketoacidosis

Diabetic ketoacidosis is a serious complication of diabetes that causes a build-up of acids called ketones in the blood. Path 30 MG Tablet is not recommended for use if you have diabetic ketoacidosis as it may further worsen your condition.

Bladder cancer

Path 30 MG Tablet may increase the risk of bladder cancer. This medicine is not recommended for use if you have bladder cancer as it may worsen your condition.

Active liver disease

Path 30 MG Tablet is not recommended for use if you have liver problems due to the increased risk of elevated liver enzyme levels and liver toxicity.

Type 1 Diabetes mellitus

Path 30 MG Tablet is not recommended for use if you have Type I diabetes (when your body does not produce insulin or makes very little insulin) as this medicine is not effective in treating the condition.
Warnings for special population

Pregnancy

Path 30 MG Tablet is not recommended for use during pregnancy unless absolutely necessary. Consult your doctor before taking this medicine if you are pregnant.

Breast-feeding

Path 30 MG Tablet is not recommended for use if you are breastfeeding as it may cause undesired effects in your infant. Consult your doctor to understand the risks and benefits before taking this medicine.
General warnings

Oedema

Oedema refers to swelling caused due to excess fluid retention in your body's tissue. Path 30 MG Tablet can cause oedema, and should be used with caution if you are the risk of developing heart failure or have fluid retention in the body. This medicine may further worsen your condition

Bone fractures

Path 30 MG Tablet should be used with caution due to the increased risk of bone fractures, especially in women.

Use in children

Path 30 MG Tablet is not recommended for use in children below 18 years of age as the safety and efficacy data are not available.

Other anti-diabetic medicines

Report the use of any other anti-diabetic medication to your doctor before beginning treatment with this medicine, as it may lead to very low blood sugar levels.

Weight gain

Monitor your body weight during treatment with Path 30 MG Tablet, as this medicine may cause weight gain.

Premenopausal ovulation

Women of childbearing potential should use Path 30 MG Tablet with caution as it may stimulate ovulation (release of a mature egg from the ovary) and increase the risk of unintended pregnancy.

Macular oedema

Macular oedema is swelling of the macula (the thin layer at the back of your eye) due to the build-up of fluid. Path 30 MG Tablet should be used with caution if you have macular oedema as this medicine may further aggravate your condition.

Driving or operating machines

Avoid driving vehicles or operating machines if you experience visual disturbances during treatment with Path 30 MG Tablet.

Missed Dose

Take the missed dose of Path 30 MG Tablet as soon as you remember. However, skip the missed dose if it is almost time for the next scheduled dose. Do not double your dose to make up for the missed dose.

Overdose

Never take more than the prescribed dose of Path 30 MG Tablet. Contact your doctor immediately in case of an overdose of this medicine.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Avoid consumption of alcohol during treatment with Path 30 MG Tablet due to the increased risk of side effects.
Interaction with Medicine

Gatifloxacin

Gemfibrozil

Insulin injection

Disease interactions

Bladder cancer

Path 30 MG Tablet should be used with caution due to the increased risk of bladder cancer.

Anaemia

Path 30 MG Tablet should be used with caution if you have anaemia (low red blood cell count) as this medicine may cause a decrease in haemoglobin (a protein in the red blood cells that helps to carry oxygen) and haematocrit (the volume of red blood cells compared to total blood volume) levels.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Path 30 MG Tablet may be taken with or without food. Take this medicine exactly as prescribed by the doctor. Do not break, crush, or chew the tablet. Swallow it whole with an adequate amount of water. Take the medicine at the same time every day for ease of remembering. Adapt healthy lifestyles such as eating a diet with low sugar content and indulging in physical activities to get maximum benefits. Regularly monitor your blood sugar levels during treatment with this medicine. Always carry a sugar candy with you to counteract the unexpected lowering of blood sugar levels.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
Path 30 MG Tablet works by improving your body's response to insulin (a chemical substance that helps control blood sugar levels) and lowering the production of sugar in the liver.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Thiazolidinediones, Antidiabetic agents

Schedule

Schedule H

Medicines.org.uk. 2021. Pioglitazone Mylan 15 mg, 30 mg, 45 mg tablets - Summary of Product Characteristics (SmPC) - (emc). [online] Available at: [Accessed 29 October 2021].

https://www.medicines.org.uk/emc/product/8836/smpc#CLINICAL_PRECAUTIONS

Pubchem.ncbi.nlm.nih.gov. 2021. Pioglitazone. [online] Available at: [Accessed 29 October 2021].

https://pubchem.ncbi.nlm.nih.gov/compound/4829#section=Biological-Half-Life

Ema.europa.eu. 2022. [online] Available at: [Accessed 9 August 2022].

https://www.ema.europa.eu/en/documents/product-information/actos-epar-product-information_en.pdf

Bbukltd.com. 2022. [online] Available at: [Accessed 9 August 2022].

https://www.bbukltd.com/wp-content/uploads/PIL//UK_PIL_Sep-2016_Pioglitazone-2.pdf
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 9 Aug 2022

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.